Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user with diffuse thinning alopecia uses a custom full cap wig for an active lifestyle, costing $450 and lasting about 10 months. They share their positive experience with the wig as an alternative for those for whom treatments like Minoxidil, finasteride, or RU58841 don't work.

Dr. Tsuji's stem cell hair multiplication procedure may offer a future solution for hair loss, but it is initially expected to be very expensive, with prices potentially decreasing over time. In the meantime, users discuss using treatments like finasteride, despite side effects, to manage hair loss.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user is considering increasing their dutasteride dose and trying clascoterone or RU58841 for hair loss stabilization. They have used finasteride, minoxidil, and dutasteride, with some success but recent setbacks.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user regrets not starting Dutasteride earlier and has been using Minoxidil and Finasteride to slow hair loss. Suggestions include switching to Dutasteride, considering a hair transplant, and using additional treatments like microneedling and topical solutions.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

The user believes neck tension and poor posture contribute to hair loss, noticing improvements with yoga and muscle relaxation. Replies suggest androgenic alopecia as the cause and recommend exercises.

The conversation is about choosing a hair transplant clinic in Seoul for an M-shaped hairline, with considerations for natural-looking results and doctor involvement. Clinics mentioned include Mojelim, Moem, Modi Hairplant, and Motion Clinic.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

Hair systems are a popular solution for hair loss, offering impressive transformations with manageable maintenance and cost. Some users prefer hair systems over medications like Minoxidil or Finasteride, while others express concerns about the permanence and visibility of these systems.

A 35-year-old man shared his hair transplant experience in Tijuana, Mexico, choosing Artline for 5,000 grafts at a lower cost than U.S. clinics. He plans to use topical minoxidil and possibly microneedling for better results.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

A user is experiencing hair loss and has been using Propecia, minoxidil, Regenepure DR, and dermarolling, with recent improvements on the left temple but worsening on the right. Suggestions include checking for vitamin deficiencies, thyroid issues, and considering dutasteride.

Oral hyaluronic acid is not beneficial for hair, as it gets broken down in the stomach and has no strong evidence supporting its effectiveness. The user is taking finasteride, dutasteride, and topical minoxidil for hair loss, but combining finasteride and dutasteride is considered redundant.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

A small spot or gap after a hair transplant is normal due to skin stretching during healing. Following post-procedure instructions is important, and the issue should resolve as swelling decreases.

People with hair loss experience emotional struggles and body dysmorphia. Treatments like minoxidil, finasteride, and dutasteride are used, but results vary and can take time.

Hair transplants have improved significantly from the old "plug" method, which left unnatural results. Modern techniques by skilled doctors can achieve natural-looking hairlines.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

Hair transplants typically involve spreading follicle extraction across the back and sides of the head to maintain an even appearance, rather than taking a solid rectangle of grafts. FUT procedures, which involve taking a strip of skin, are less common now due to advancements in techniques like FUE, which heal well and are less invasive.

The conversation discusses hair loss treatments, specifically using 2.5mg dutasteride, minoxidil, and sometimes RU58841, with a focus on diffuse thinning versus recession. It also touches on the impact of estrogen levels on hair density.

Hair loss may be influenced more by inflammation, microbiome imbalances, and gut health than DHT. Treatments discussed include minoxidil, finasteride, RU58841, fecal microbiota transplants, and JAK inhibitors.

A female user discusses hair loss possibly caused by wearing a hijab, considering treatments like derma stamping, hair serum, Nizoral shampoo, rosemary/castor oil, and possibly a hair transplant. Others suggest traction alopecia from hijab use and recommend consulting a dermatologist, with treatments like spironolactone and minoxidil.

DHT itch often occurs in cycles or flare-ups, particularly around the temples and crown. Treatments like finasteride, dutasteride, and topical minoxidil can reduce or eliminate the itch.